Skip to content Skip to footer
Subscribe Now
Viewpoints_Mike Crichton
VIEWPOINTS
PharmaShots Interview: GSK’s Mike Crichton Shares Insights on the Approval of Benlysta in Europe
In an interview with PharmaShots, Mike Crichton, Senior Vice President, Global Therapy Area Head, Specialty & Primary Care at GSK shares his views on the European Commission's approval of Benlysta (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (LN). Shots: The European Commission approved the expanded use of GSK's…
June 8, 20210Comments
Viewpoints_Dr. Gill Diamond and Joshua McClure
VIEWPOINTS
PharmaShots Interview: Maxwell Biosciences’ Dr. Gill Diamond and Joshua McClure Share Insights Novel Peptoids with Potent Antiviral Activity Against HSV-1 and SARS-CoV-2
In an interview with PharmaShots, Dr. Gill Diamond, Scientific Advisory Board Member and Joshua McClure, CEO and Co-founder of Maxwell Biosciences share their views on the news findings of the company published in MDI that demonstrated that several peptoids exhibit potent in vitro antiviral activity against both HSV-1 and SARS-CoV-2. Shots: The studies showed that antiviral peptoids…
June 7, 20210Comments
Viewpoints_Rich Colvin
VIEWPOINTS
PharmaShots Interview: bluebird bio’s Rich Colvin Shares Insights on the Skysona to Treat Early Cerebral Adrenoleukodystrophy
In an interview with PharmaShots, Rich Colvin, M.D., Ph.D., Interim Chief Medical Officer at bluebird bio shares his views on the Skysona and its working on CALD patients. Shots: If granted marketing authorization, Skysona would be the first approved one-time gene therapy for CALD which is a rare neurogenerative disease with typically childhood onset The CHMP opinion…
June 4, 20210Comments
Insights+ Key Biosimilars Events of May 2021
INSIGHTS+
Insights+ Key Biosimilars Events of May 2021
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of May, Samsung initiated patient enrollment in the P-III…
June 3, 20210Comments
Viewpoints_Ken Keller
VIEWPOINTS
PharmaShots Interview: Daiichi Sankyo’s Ken Keller Shares Insights on NICE Recommendation for Enhertu in HER2 Positive Breast Cancer
In an interview with PharmaShots, Ken Keller, President and Chief Executive Officer at Daiichi Sankyo and Global Head of the Daiichi Sankyo Oncology Business shared his views on the NICE CDF recommendation for Enhertu in unresectable or metastatic HER2 positive breast cancer and the company's growth and pipeline. Shots: The recommendation from NICE is based on the…
June 2, 20210Comments
Viewpoints_Neil Solomons
VIEWPOINTS
PharmaShots Interview: Aurinia’s Neil Solomons Shares Insights on the Lupkynis
In an interview with PharmaShots, Neil Solomons, Co-founder and Chief Medical Officer of Aurinia shared his views on the data of Lupkynis (voclosporin) presented at the National Kidney Foundation 2021 Spring Clinical Meetings. Shots: New data analysis from the AURORA and AURA clinical studies shows that Aurinia's therapy demonstrated efficacy across all LN biopsy classes. These data show that treatment…
June 1, 20210Comments
Viewpoints_Neil Moat
VIEWPOINTS
PharmaShots Interview: Abbott’s Neil Moat Shares Insights on the Next Generation TriClip Transcatheter Tricuspid Valve Repair System
In an interview with PharmaShots, Neil Moat, M.D., Chief Medical Officer of Abbott's Structural Heart Business shares his views on the CE mark approval of first-of-its-kind TriClip device. Shots: The new iteration of the device, called TriClip G4, offers new clip sizes and an enhanced leaflet grasping feature for physicians to further customize treatment to the complex tricuspid valve…
May 31, 20210Comments
Viewpoints_Dr. Fahar Merchant
VIEWPOINTS
PharmaShots Interview: Medicenna’s Dr. Fahar Merchant Shares Insights on the Bispecific Superkines
In an interview with PharmaShots, Dr. Fahar Merchant, CEO of Medicenna shares his views on the data of a new type of interleukin called bispecific Superkines, presented at AACR 2021   Shots: Bispecific Superkines can attack cold tumors, weakening the protection given to it by the tumor microenvironment and revealing it to the immune system Medicenna focuses on…
May 26, 20210Comments

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]